Introduction to Orforglipron (Foundayo)
Orforglipron, branded as Foundayo, is designed for weight management in adults with a BMI of 30 or greater, or a BMI of 27 and above with weight-related comorbidities. This prescription-only GLP-1 receptor agonist is taken as a once-daily oral tablet.
Is Orforglipron Authorised in the UK?
Orforglipron was authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on 10 August 2026, making the UK the first European country to approve it. It is not currently available via the NHS, but decisions regarding NHS provision will involve processes including NICE evaluation.
The MHRA has also authorised orforglipron to improve glycaemic control in adults with insufficiently controlled type 2 diabetes. This article focuses on its authorised use for weight management.
Availability and Future Supply
While Orforglipron’s commercial availability in the UK has yet to be confirmed, The Chemist Live intends to offer it once it becomes accessible to us. You can join our waiting list or explore existing weight-loss treatment options through a free assessment with our pharmacist team.
Orforglipron and Foundayo: Understanding the Names
Foundayo is the commercial brand name for Orforglipron. They are the same medication, and healthcare providers can prescribe it using either name confidently.
How Does Orforglipron Work?
Orforglipron acts by mimicking the hormone glucagon-like peptide-1 (GLP-1). It targets the brain areas responsible for feelings of fullness, supporting decreased food intake, which can aid in weight loss for those meeting medical criteria.
Who Is Orforglipron Suitable For?
This medication is suitable for adults with a BMI of 30 or higher, or a BMI between 27 and 30 with at least one related comorbidity. It is to be used alongside a calorie-reduced diet and increased physical activity.
Dosage Schedule
Treatment starts at 0.8 mg, escalating through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg doses, with each level maintained for at least one month. It can be taken at any time of day, with no restrictions on food or water.
How is orforglipron different from oral Wegovy?
Foundayo (orforglipron) and oral Wegovy (semaglutide tablets) are both once-daily tablets authorised for weight management. They are different medicines, with different active ingredients, and they are taken differently.
Foundayo contains orforglipron and is made by Eli Lilly. Its SmPC states that it is taken once daily at any time of day, without food or water restrictions. The tablet is swallowed whole and should not be broken, crushed or chewed.
Oral Wegovy contains semaglutide and is made by Novo Nordisk. Its SmPC states that it is taken on an empty stomach after a fasting period of at least eight hours and swallowed whole with a sip of water—up to half a glass, equivalent to 120 mL. Patients should then wait at least 30 minutes before eating, drinking or taking other oral medicines.
Both medicines are started at a low dose and increased in steps. Foundayo’s SmPC requires a minimum of 30 days at the current dose before each increase. Oral Wegovy’s SmPC specifies a minimum duration of one month at each dose level.
These are differences in how the medicines are taken, not a ranking of the treatments. Neither medicine is presented as preferable. Whether either treatment is appropriate is a clinical decision for an authorised prescriber.
Potential Side Effects
Common side effects include nausea, constipation, diarrhoea, vomiting, dyspepsia, and abdominal pain. Discuss these with a healthcare provider to determine suitability.
Additional Considerations
Monitoring how your body responds is crucial, and regular check-ins with healthcare providers can help manage side effects.
FAQs
What is Orforglipron used for?
Orforglipron is authorised for weight management in adults who meet the eligibility criteria.
Is Orforglipron available in the UK?
Orforglipron is authorised but not yet commercially available in the UK.
Is Foundayo the same as Orforglipron?
Yes, Foundayo is the brand name for Orforglipron.
What are the common side effects of Orforglipron?
Common side effects include nausea, constipation, diarrhoea, vomiting, indigestion, and abdominal pain.
How should Orforglipron be taken?
It can be taken daily at any time, with no food or water restrictions.
For those exploring weight-loss treatment options, start a free assessment with our pharmacists today.
This educational content reflects information from MHRA, offering accurate medical guidance about Orforglipron in the UK. Always seek personalised advice from licensed professionals.
